Related Experiment Video
Updated: Dec 3, 2025
Author Spotlight: Advancing the Analysis of Plasma Extracellular Vesicle Proteome for Cardiovascular Biomarker Studies
Published on: January 31, 2025
Using proximity extension proteomics assay to identify biomarkers associated with infarct size and ejection fraction
Moman A Mohammad1, Sasha Koul1, Anna Egerstedt1
1Department of Cardiology, Clinical Sciences, Lund University, Skane University Hospital, Lund, Sweden.
Insights
Nine proteins in the blood show changes after ST-elevation myocardial infarction (STEMI), correlating with heart damage and function. Interleukin-6 (IL-6) and ST2 had the strongest links to infarct size and left ventricular ejection fraction (LVEF).
Area of Science:
- Cardiovascular Medicine
- Proteomics
- Biomarker Discovery
Background:
- Plasma protein levels change after ST-elevation myocardial infarction (STEMI), potentially offering prognostic insights.
- Assessing these changes is crucial for understanding post-STEMI cardiac remodeling and outcomes.
Purpose of the Study:
- To perform a large-scale proteomic analysis in STEMI patients.
- To correlate circulating protein levels with infarct size and left ventricular ejection fraction (LVEF) post-STEMI.
Main Methods:
- Analyzed 131 cardiovascular and inflammatory proteins using a multiplex proximity extension assay.
- Collected blood samples at multiple time points (baseline, 6, 24, 96 hours) from STEMI patients in the CHILL-MI trial.
- Utilized cardiac magnetic resonance imaging (CMR) for infarct size and LVEF assessment and linear regression with bootstrap resampling for analysis.
Main Results:
- Identified nine proteins associated with infarct size or LVEF.
- Five proteins (ST2, IL-6, Pentraxin-3, IL-10, Renin, Myoglobin) showed elevated levels with larger infarct size or worse LVEF.
- Four proteins (TRAIL, TIRC, IL-16, Cystatin B) showed inverse relationships with LVEF and infarct size.
Conclusions:
- Circulating inflammatory and cardiovascular proteins in the acute/sub-acute phase of STEMI are related to infarct size and LVEF.
- Interleukin-6 (IL-6) and ST2 demonstrated the strongest associations with infarct size and LVEF post-STEMI.
Abstract:
Plasma concentrations of many cardiovascular and inflammatory proteins are altered after ST-elevation myocardial infarction (STEMI) and may provide prognostic information. We conducted a large-scale proteomic analysis in patients with STEMI, correlating protein levels to infarct size and left ventricular ejection fraction (LVEF) determined with cardiac magnetic resonance imaging. We analysed 131 cardiovascular and inflammatory proteins using a multiplex proximity extension assay and blood samples obtained at baseline, 6, 24, and 96 h from the randomised clinical trial CHILL-MI. Cardiac magnetic resonance imaging data at 4 ± 2 days and 6 months were available as per trial protocol. Using a linear regression model with bootstrap resampling and false discovery rate adjustment we identified five proteins (ST2, interleukin-6, pentraxin-3, interleukin-10, renin, and myoglobin) with elevated values corresponding to larger infarct size or worse LVEF and four proteins (TNF-related apoptosis-inducing ligand, TNF-related activation induced cytokine, interleukin-16, and cystatin B) with values inversely related to LVEF and infarct size, concluding that among 131 circulating inflammatory and cardiovascular proteins in the acute and sub-acute phase of STEMI, nine showed a relationship with infarct size and LVEF post-STEMI, with IL-6 and ST2 exhibiting the strongest association.
More Related Videos
09:00A Streamlined Approach for Mass Spectrometry-Based Proteomics Using Selected Tissue Regions
Published on: April 18, 2025
10:12A Sensitive and Specific Quantitation Method for Determination of Serum Cardiac Myosin Binding Protein-C by Electrochemiluminescence Immunoassay
Published on: August 8, 2013
Related Concept Videos
01:33Proteomics
Proteomics is the study of proteomes' function. It involves the large-scale systematic study of the proteome to denote the protein complement expressed by a genome. Scientist Mark Wilkins coined the term...
01:20Blood Studies for Cardiovascular System I: Cardiac Biomarkers
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...